Cargando…

Biopsy-confirmed fenofibrate-induced severe jaundice: A case report

BACKGROUND: Drug-induced liver injury (DILI) is the leading cause of acute liver failure in the United States. DILI is mainly caused by painkillers and fever reducers, and it is often characterized by the type of hepatic injury (hepatocellular or cholestatic). This report presents a case of fenofibr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hye Young, Lee, Ae-Ra, Yoo, Jeong-Ju, Chin, Susie, Kim, Sang Gyune, Kim, Young Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567496/
https://www.ncbi.nlm.nih.gov/pubmed/34786416
http://dx.doi.org/10.12998/wjcc.v9.i30.9295
_version_ 1784594246075940864
author Lee, Hye Young
Lee, Ae-Ra
Yoo, Jeong-Ju
Chin, Susie
Kim, Sang Gyune
Kim, Young Seok
author_facet Lee, Hye Young
Lee, Ae-Ra
Yoo, Jeong-Ju
Chin, Susie
Kim, Sang Gyune
Kim, Young Seok
author_sort Lee, Hye Young
collection PubMed
description BACKGROUND: Drug-induced liver injury (DILI) is the leading cause of acute liver failure in the United States. DILI is mainly caused by painkillers and fever reducers, and it is often characterized by the type of hepatic injury (hepatocellular or cholestatic). This report presents a case of fenofibrate-induced severe jaundice in a 65-year-old Korean male with no prior history of liver disease. We offer a strategy for patients who present signs of severe liver injury with jaundice and high elevations in serum transaminases. CASE SUMMARY: A 65-year-old male visited the gastroenterology outpatient clinic of a tertiary hospital due to increased levels of liver enzyme and total bilirubin which were incidentally detected through a preoperative screening test. Abdominal ultrasound and computed tomography showed no biliary obstruction or non-specific findings in the liver. Liver biopsy was performed and the patient was finally diagnosed with acute cholestatic hepatitis. Following the biopsy, steroid therapy was initiated and after 3 wk of treatment, the total bilirubin level was reduced to 7.22 mg/dL. CONCLUSION: In patients with hyperlipidemia, treatment including fenofibric acid induces rare complications such as severe jaundice and acute cholestatic hepatitis, warranting clinical attention.
format Online
Article
Text
id pubmed-8567496
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-85674962021-11-15 Biopsy-confirmed fenofibrate-induced severe jaundice: A case report Lee, Hye Young Lee, Ae-Ra Yoo, Jeong-Ju Chin, Susie Kim, Sang Gyune Kim, Young Seok World J Clin Cases Case Report BACKGROUND: Drug-induced liver injury (DILI) is the leading cause of acute liver failure in the United States. DILI is mainly caused by painkillers and fever reducers, and it is often characterized by the type of hepatic injury (hepatocellular or cholestatic). This report presents a case of fenofibrate-induced severe jaundice in a 65-year-old Korean male with no prior history of liver disease. We offer a strategy for patients who present signs of severe liver injury with jaundice and high elevations in serum transaminases. CASE SUMMARY: A 65-year-old male visited the gastroenterology outpatient clinic of a tertiary hospital due to increased levels of liver enzyme and total bilirubin which were incidentally detected through a preoperative screening test. Abdominal ultrasound and computed tomography showed no biliary obstruction or non-specific findings in the liver. Liver biopsy was performed and the patient was finally diagnosed with acute cholestatic hepatitis. Following the biopsy, steroid therapy was initiated and after 3 wk of treatment, the total bilirubin level was reduced to 7.22 mg/dL. CONCLUSION: In patients with hyperlipidemia, treatment including fenofibric acid induces rare complications such as severe jaundice and acute cholestatic hepatitis, warranting clinical attention. Baishideng Publishing Group Inc 2021-10-26 2021-10-26 /pmc/articles/PMC8567496/ /pubmed/34786416 http://dx.doi.org/10.12998/wjcc.v9.i30.9295 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Case Report
Lee, Hye Young
Lee, Ae-Ra
Yoo, Jeong-Ju
Chin, Susie
Kim, Sang Gyune
Kim, Young Seok
Biopsy-confirmed fenofibrate-induced severe jaundice: A case report
title Biopsy-confirmed fenofibrate-induced severe jaundice: A case report
title_full Biopsy-confirmed fenofibrate-induced severe jaundice: A case report
title_fullStr Biopsy-confirmed fenofibrate-induced severe jaundice: A case report
title_full_unstemmed Biopsy-confirmed fenofibrate-induced severe jaundice: A case report
title_short Biopsy-confirmed fenofibrate-induced severe jaundice: A case report
title_sort biopsy-confirmed fenofibrate-induced severe jaundice: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567496/
https://www.ncbi.nlm.nih.gov/pubmed/34786416
http://dx.doi.org/10.12998/wjcc.v9.i30.9295
work_keys_str_mv AT leehyeyoung biopsyconfirmedfenofibrateinducedseverejaundiceacasereport
AT leeaera biopsyconfirmedfenofibrateinducedseverejaundiceacasereport
AT yoojeongju biopsyconfirmedfenofibrateinducedseverejaundiceacasereport
AT chinsusie biopsyconfirmedfenofibrateinducedseverejaundiceacasereport
AT kimsanggyune biopsyconfirmedfenofibrateinducedseverejaundiceacasereport
AT kimyoungseok biopsyconfirmedfenofibrateinducedseverejaundiceacasereport